• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
SDX 0.00% 7.0¢

SIENNA CANCER DIAGNOSTICS LIMITED - Discussion

Currently unlisted. Proposed listing date: 3 AUGUST 2017 11:00AM AEST watchlist Created with Sketch. Add to my watchlist

Sienna Cancer Diagnostics Limited is an Australia-based biotechnology company. The... Sienna Cancer Diagnostics Limited is an Australia-based biotechnology company. The Company is focused on the development and commercialization of novel in vitro diagnostic (IVD) tests for detection and monitoring of cancer. The Company manufactures IVD products for pathology laboratories to use in testing services. The Company’s product Anti-human telomerase reverse transcriptase (hTERT) antibody (SCD-A7) is based on a technology for the detection of biomarker telomerase.The hTERT can be used in pathology labs. Anti-hTERT is targeted against hTERT protein component of the telomerase complex which acts to extend and maintain telomeres in cells.More

Sienna Cancer Diagnostics Limited

Forum Tag Subject View Poster Comments Created with Sketch. Views Created with Sketch. Likes Created with Sketch. Date Created with Sketch.
ASX - By Stock SDX Re: Ann: ASX Notice - Admission and Quotation Thread Bigsky 31 9.6K 0 03/08/17
03/08/17 ASX - By Stock Thread Comments Created with Sketch. 31 Views Created with Sketch. 9.6K Likes Created with Sketch. 0
ASX News
ASX News
ASX News
ASX News
ASX News
ASX News
ASX News
ASX News
ASX News
ASX News
ASX News
ASX News
ASX News
ASX News
ASX News
ASX News
ASX News
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.